TY - JOUR AU - Chapman, P. B. AU - Hauschild, A. AU - Robert, C. AU - Haanen, J. B. AU - Ascierto, P. AU - Larkin, J. PY - 2011 DA - 2011// TI - Improved survival with vemurafenib in melanoma with BRAF V600E mutation JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1103782 DO - 10.1056/NEJMoa1103782 ID - Chapman2011 ER - TY - JOUR AU - Siegelin, M. D. AU - Borczuk, A. C. PY - 2014 DA - 2014// TI - Epidermal growth factor receptor mutations in lung adenocarcinoma JO - Lab Invest VL - 94 UR - https://doi.org/10.1038/labinvest.2013.147 DO - 10.1038/labinvest.2013.147 ID - Siegelin2014 ER - TY - JOUR AU - Sharma, P. AU - Hu-Lieskovan, S. AU - Wargo, J. A. AU - Ribas, A. PY - 2017 DA - 2017// TI - Primary, adaptive, and acquired resistance to cancer immunotherapy JO - Cell VL - 168 UR - https://doi.org/10.1016/j.cell.2017.01.017 DO - 10.1016/j.cell.2017.01.017 ID - Sharma2017 ER - TY - JOUR AU - Burrell, R. A. AU - Swanton, C. PY - 2014 DA - 2014// TI - Tumour heterogeneity and the evolution of polyclonal drug resistance JO - Mol Oncol VL - 8 UR - https://doi.org/10.1016/j.molonc.2014.06.005 DO - 10.1016/j.molonc.2014.06.005 ID - Burrell2014 ER - TY - JOUR AU - Almendro, V. AU - Marusyk, A. AU - Polyak, K. PY - 2013 DA - 2013// TI - Cellular heterogeneity and molecular evolution in cancer JO - Annu Rev Pathol VL - 8 UR - https://doi.org/10.1146/annurev-pathol-020712-163923 DO - 10.1146/annurev-pathol-020712-163923 ID - Almendro2013 ER - TY - JOUR AU - Vogelstein, B. AU - Papadopoulos, N. AU - Velculescu, V. E. AU - Zhou, S. AU - Diaz, L. A. AU - Kinzler, K. W. PY - 2013 DA - 2013// TI - Cancer genome landscapes JO - Science VL - 339 UR - https://doi.org/10.1126/science.1235122 DO - 10.1126/science.1235122 ID - Vogelstein2013 ER - TY - JOUR AU - Hata, A. N. AU - Niederst, M. J. AU - Archibald, H. L. AU - Gomez-Caraballo, M. AU - Siddiqui, F. M. AU - Mulvey, H. E. PY - 2016 DA - 2016// TI - Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition JO - Nat Med VL - 22 UR - https://doi.org/10.1038/nm.4040 DO - 10.1038/nm.4040 ID - Hata2016 ER - TY - JOUR AU - Hiley, C. AU - Bruin, E. C. AU - McGranahan, N. AU - Swanton, C. PY - 2014 DA - 2014// TI - Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine JO - Genome Biol VL - 15 UR - https://doi.org/10.1186/s13059-014-0453-8 DO - 10.1186/s13059-014-0453-8 ID - Hiley2014 ER - TY - JOUR AU - McGranahan, N. AU - Swanton, C. PY - 2015 DA - 2015// TI - Biological and therapeutic impact of intratumor heterogeneity in cancer evolution JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2014.12.001 DO - 10.1016/j.ccell.2014.12.001 ID - McGranahan2015 ER - TY - JOUR AU - Gerlinger, M. AU - Rowan, A. J. AU - Horswell, S. AU - Larkin, J. AU - Endesfelder, D. AU - Gronroos, E. PY - 2012 DA - 2012// TI - Intratumor heterogeneity and branched evolution revealed by multiregion sequencing JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1113205 DO - 10.1056/NEJMoa1113205 ID - Gerlinger2012 ER - TY - JOUR AU - Johnson, D. B. AU - Menzies, A. M. AU - Zimmer, L. AU - Eroglu, Z. AU - Ye, F. AU - Zhao, S. PY - 2015 DA - 2015// TI - Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.08.022 DO - 10.1016/j.ejca.2015.08.022 ID - Johnson2015 ER - TY - JOUR AU - Shi, H. AU - Hugo, W. AU - Kong, X. AU - Hong, A. AU - Koya, R. C. AU - Moriceau, G. PY - 2014 DA - 2014// TI - Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-13-0642 DO - 10.1158/2159-8290.CD-13-0642 ID - Shi2014 ER - TY - JOUR AU - Belchis, D. A. AU - Tseng, L. H. AU - Gniadek, T. AU - Haley, L. AU - Lokhandwala, P. AU - Illei, P. PY - 2016 DA - 2016// TI - Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma JO - Oncotarget VL - 7 ID - Belchis2016 ER - TY - JOUR AU - Piotrowska, Z. AU - Niederst, M. J. AU - Karlovich, C. A. AU - Wakelee, H. A. AU - Neal, J. W. AU - Mino-Kenudson, M. PY - 2015 DA - 2015// TI - Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0399 DO - 10.1158/2159-8290.CD-15-0399 ID - Piotrowska2015 ER - TY - JOUR AU - Chabon, J. J. AU - Simmons, A. D. AU - Lovejoy, A. F. AU - Esfahani, M. S. AU - Newman, A. M. AU - Haringsma, H. J. PY - 2016 DA - 2016// TI - Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms11815 DO - 10.1038/ncomms11815 ID - Chabon2016 ER - TY - JOUR AU - Misale, S. AU - Arena, S. AU - Lamba, S. AU - Siravegna, G. AU - Lallo, A. AU - Hobor, S. PY - 2014 DA - 2014// TI - Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3007947 DO - 10.1126/scitranslmed.3007947 ID - Misale2014 ER - TY - JOUR AU - Russo, M. AU - Siravegna, G. AU - Blaszkowsky, L. S. AU - Corti, G. AU - Crisafulli, G. AU - Ahronian, L. G. PY - 2016 DA - 2016// TI - Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-15-1283 DO - 10.1158/2159-8290.CD-15-1283 ID - Russo2016 ER - TY - JOUR AU - Morris, L. G. AU - Riaz, N. AU - Desrichard, A. AU - Senbabaoglu, Y. AU - Hakimi, A. A. AU - Makarov, V. PY - 2016 DA - 2016// TI - Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival JO - Oncotarget VL - 7 ID - Morris2016 ER - TY - JOUR AU - Normanno, N. AU - Rachiglio, A. M. AU - Lambiase, M. AU - Martinelli, E. AU - Fenizia, F. AU - Esposito, C. PY - 2015 DA - 2015// TI - Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv176 DO - 10.1093/annonc/mdv176 ID - Normanno2015 ER - TY - JOUR AU - Esposito, A. AU - Criscitiello, C. AU - Locatelli, M. AU - Milano, M. AU - Curigliano, G. PY - 2016 DA - 2016// TI - Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies JO - Pharmacol Ther VL - 157 UR - https://doi.org/10.1016/j.pharmthera.2015.11.007 DO - 10.1016/j.pharmthera.2015.11.007 ID - Esposito2016 ER - TY - JOUR AU - Pao, W. AU - Miller, V. A. AU - Politi, K. A. AU - Riely, G. J. AU - Somwar, R. AU - Zakowski, M. F. PY - 2005 DA - 2005// TI - Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain JO - PLoS Med VL - 2 UR - https://doi.org/10.1371/journal.pmed.0020073 DO - 10.1371/journal.pmed.0020073 ID - Pao2005 ER - TY - JOUR AU - Rodrik-Outmezguine, V. S. AU - Okaniwa, M. AU - Yao, Z. AU - Novotny, C. J. AU - McWhirter, C. AU - Banaji, A. PY - 2016 DA - 2016// TI - Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor JO - Nature VL - 534 ID - Rodrik-Outmezguine2016 ER - TY - JOUR AU - Kemper, K. AU - Krijgsman, O. AU - Cornelissen-Steijger, P. AU - Shahrabi, A. AU - Weeber, F. AU - Song, J. Y. PY - 2015 DA - 2015// TI - Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts JO - EMBO Mol Med VL - 7 UR - https://doi.org/10.15252/emmm.201404914 DO - 10.15252/emmm.201404914 ID - Kemper2015 ER - TY - JOUR AU - Wagle, N. AU - Allen, E. M. AU - Treacy, D. J. AU - Frederick, D. T. AU - Cooper, Z. A. AU - Taylor-Weiner, A. PY - 2014 DA - 2014// TI - MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-13-0631 DO - 10.1158/2159-8290.CD-13-0631 ID - Wagle2014 ER - TY - JOUR AU - Ahronian, L. G. AU - Sennott, E. M. AU - Allen, E. M. AU - Wagle, N. AU - Kwak, E. L. AU - Faris, J. E. PY - 2015 DA - 2015// TI - Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-14-1518 DO - 10.1158/2159-8290.CD-14-1518 ID - Ahronian2015 ER - TY - JOUR AU - Ahronian, L. G. AU - Corcoran, R. B. PY - 2016 DA - 2016// TI - Effective MAPK inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations JO - Mol Cell Oncol VL - 3 UR - https://doi.org/10.1080/23723556.2015.1048405 DO - 10.1080/23723556.2015.1048405 ID - Ahronian2016 ER - TY - JOUR AU - Nanjo, S. AU - Yamada, T. AU - Nishihara, H. AU - Takeuchi, S. AU - Sano, T. AU - Nakagawa, T. PY - 2013 DA - 2013// TI - Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0084700 DO - 10.1371/journal.pone.0084700 ID - Nanjo2013 ER - TY - JOUR AU - Ercan, D. AU - Choi, H. G. AU - Yun, C. H. AU - Capelletti, M. AU - Xie, T. AU - Eck, M. J. PY - 2015 DA - 2015// TI - EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2789 DO - 10.1158/1078-0432.CCR-14-2789 ID - Ercan2015 ER - TY - JOUR AU - Eberlein, C. A. AU - Stetson, D. AU - Markovets, A. A. AU - Al-Kadhimi, K. J. AU - Lai, Z. AU - Fisher, P. R. PY - 2015 DA - 2015// TI - Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3167 DO - 10.1158/0008-5472.CAN-14-3167 ID - Eberlein2015 ER - TY - JOUR AU - Ercan, D. AU - Xu, C. AU - Yanagita, M. AU - Monast, C. S. AU - Pratilas, C. A. AU - Montero, J. PY - 2012 DA - 2012// TI - Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0103 DO - 10.1158/2159-8290.CD-12-0103 ID - Ercan2012 ER - TY - JOUR AU - Tricker, E. M. AU - Xu, C. AU - Uddin, S. AU - Capelletti, M. AU - Ercan, D. AU - Ogino, A. PY - 2015 DA - 2015// TI - Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0063 DO - 10.1158/2159-8290.CD-15-0063 ID - Tricker2015 ER - TY - JOUR AU - Corcoran, R. B. AU - Ebi, H. AU - Turke, A. B. AU - Coffee, E. M. AU - Nishino, M. AU - Cogdill, A. P. PY - 2012 DA - 2012// TI - EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-11-0341 DO - 10.1158/2159-8290.CD-11-0341 ID - Corcoran2012 ER - TY - JOUR AU - Koyama, S. AU - Akbay, E. A. AU - Li, Y. Y. AU - Herter-Sprie, G. S. AU - Buczkowski, K. A. AU - Richards, W. G. PY - 2016 DA - 2016// TI - Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms10501 DO - 10.1038/ncomms10501 ID - Koyama2016 ER - TY - JOUR AU - Chandarlapaty, S. PY - 2012 DA - 2012// TI - Negative feedback and adaptive resistance to the targeted therapy of cancer JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0018 DO - 10.1158/2159-8290.CD-12-0018 ID - Chandarlapaty2012 ER - TY - JOUR AU - Chen, C. C. AU - Lee, K. D. AU - Pai, M. Y. AU - Chu, P. Y. AU - Hsu, C. C. AU - Chiu, C. C. PY - 2015 DA - 2015// TI - Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells JO - Cancer Cell Int VL - 15 UR - https://doi.org/10.1186/s12935-015-0248-3 DO - 10.1186/s12935-015-0248-3 ID - Chen2015 ER - TY - JOUR AU - Gower, A. AU - Hsu, W. H. AU - Hsu, S. T. AU - Wang, Y. AU - Giaccone, G. PY - 2016 DA - 2016// TI - EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer JO - Mol Oncol VL - 10 UR - https://doi.org/10.1016/j.molonc.2015.11.007 DO - 10.1016/j.molonc.2015.11.007 ID - Gower2016 ER - TY - JOUR AU - Biddle, A. AU - Gammon, L. AU - Liang, X. AU - Costea, D. E. AU - Mackenzie, I. C. PY - 2016 DA - 2016// TI - Phenotypic plasticity determines cancer stem cell therapeutic resistance in oral squamous cell carcinoma JO - EBioMedicine VL - 4 UR - https://doi.org/10.1016/j.ebiom.2016.01.007 DO - 10.1016/j.ebiom.2016.01.007 ID - Biddle2016 ER - TY - JOUR AU - Niederst, M. J. AU - Sequist, L. V. AU - Poirier, J. T. AU - Mermel, C. H. AU - Lockerman, E. L. AU - Garcia, A. R. PY - 2015 DA - 2015// TI - RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms7377 DO - 10.1038/ncomms7377 ID - Niederst2015 ER - TY - JOUR AU - Ribas, A. AU - Hamid, O. AU - Daud, A. AU - Hodi, F. S. AU - Wolchok, J. D. AU - Kefford, R. PY - 2016 DA - 2016// TI - Association of pembrolizumab with tumor response and survival among patients with advanced melanoma JO - JAMA VL - 315 UR - https://doi.org/10.1001/jama.2016.4059 DO - 10.1001/jama.2016.4059 ID - Ribas2016 ER - TY - JOUR AU - Zaretsky, J. M. AU - Garcia-Diaz, A. AU - Shin, D. S. AU - Escuin-Ordinas, H. AU - Hugo, W. AU - Hu-Lieskovan, S. PY - 2016 DA - 2016// TI - Mutations associated with acquired resistance to PD-1 blockade in melanoma JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1604958 DO - 10.1056/NEJMoa1604958 ID - Zaretsky2016 ER - TY - JOUR AU - Restifo, N. P. AU - Marincola, F. M. AU - Kawakami, Y. AU - Taubenberger, J. AU - Yannelli, J. R. AU - Rosenberg, S. A. PY - 1996 DA - 1996// TI - Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy JO - J Natl Cancer Inst VL - 88 UR - https://doi.org/10.1093/jnci/88.2.100 DO - 10.1093/jnci/88.2.100 ID - Restifo1996 ER - TY - JOUR AU - Sucker, A. AU - Zhao, F. AU - Real, B. AU - Heeke, C. AU - Bielefeld, N. AU - Mabetaen, S. PY - 2014 DA - 2014// TI - Genetic evolution of T-cell resistance in the course of melanoma progression JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-14-0567 DO - 10.1158/1078-0432.CCR-14-0567 ID - Sucker2014 ER - TY - JOUR AU - Frederick, D. T. AU - Piris, A. AU - Cogdill, A. P. AU - Cooper, Z. A. AU - Lezcano, C. AU - Ferrone, C. R. PY - 2013 DA - 2013// TI - BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-1630 DO - 10.1158/1078-0432.CCR-12-1630 ID - Frederick2013 ER - TY - JOUR AU - Cooper, Z. A. AU - Frederick, D. T. AU - Juneja, V. R. AU - Sullivan, R. J. AU - Lawrence, D. P. AU - Piris, A. PY - 2013 DA - 2013// TI - BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes JO - Oncoimmunology VL - 2 UR - https://doi.org/10.4161/onci.26615 DO - 10.4161/onci.26615 ID - Cooper2013 ER - TY - JOUR AU - Hu-Lieskovan, S. AU - Robert, L. AU - Homet Moreno, B. AU - Ribas, A. PY - 2014 DA - 2014// TI - Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.52.1377 DO - 10.1200/JCO.2013.52.1377 ID - Hu-Lieskovan2014 ER - TY - JOUR AU - Zhao, Z. M. AU - Zhao, B. AU - Bai, Y. AU - Iamarino, A. AU - Gaffney, S. G. AU - Schlessinger, J. PY - 2016 DA - 2016// TI - Early and multiple origins of metastatic lineages within primary tumors JO - Proc Natl Acad Sci U S A VL - 113 UR - https://doi.org/10.1073/pnas.1525677113 DO - 10.1073/pnas.1525677113 ID - Zhao2016 ER - TY - JOUR AU - Brastianos, P. K. AU - Carter, S. L. AU - Santagata, S. AU - Cahill, D. P. AU - Taylor-Weiner, A. AU - Jones, R. T. PY - 2015 DA - 2015// TI - Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0369 DO - 10.1158/2159-8290.CD-15-0369 ID - Brastianos2015 ER - TY - JOUR AU - Kwak, E. L. AU - Ahronian, L. G. AU - Siravegna, G. AU - Mussolin, B. AU - Godfrey, J. T. AU - Clark, J. W. PY - 2015 DA - 2015// TI - Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0748 DO - 10.1158/2159-8290.CD-15-0748 ID - Kwak2015 ER - TY - JOUR AU - Dawson, S. J. AU - Tsui, D. W. AU - Murtaza, M. AU - Biggs, H. AU - Rueda, O. M. AU - Chin, S. F. PY - 2013 DA - 2013// TI - Analysis of circulating tumor DNA to monitor metastatic breast cancer JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1213261 DO - 10.1056/NEJMoa1213261 ID - Dawson2013 ER - TY - JOUR AU - Higgins, M. J. AU - Jelovac, D. AU - Barnathan, E. AU - Blair, B. AU - Slater, S. AU - Powers, P. PY - 2012 DA - 2012// TI - Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-2696 DO - 10.1158/1078-0432.CCR-11-2696 ID - Higgins2012 ER - TY - JOUR AU - Diaz, L. A. AU - Williams, R. T. AU - Wu, J. AU - Kinde, I. AU - Hecht, J. R. AU - Berlin, J. PY - 2012 DA - 2012// TI - The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers JO - Nature VL - 486 ID - Diaz2012 ER - TY - JOUR AU - Misale, S. AU - Yaeger, R. AU - Hobor, S. AU - Scala, E. AU - Janakiraman, M. AU - Liska, D. PY - 2012 DA - 2012// TI - Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer JO - Nature VL - 486 ID - Misale2012 ER - TY - JOUR AU - Bettegowda, C. AU - Sausen, M. AU - Leary, R. J. AU - Kinde, I. AU - Wang, Y. AU - Agrawal, N. PY - 2014 DA - 2014// TI - Detection of circulating tumor DNA in early- and late-stage human malignancies JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3007094 DO - 10.1126/scitranslmed.3007094 ID - Bettegowda2014 ER - TY - JOUR AU - Yanagita, M. AU - Redig, A. J. AU - Paweletz, C. P. AU - Dahlberg, S. E. AU - O’Connell, A. AU - Feeney, N. PY - 2016 DA - 2016// TI - A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0909 DO - 10.1158/1078-0432.CCR-16-0909 ID - Yanagita2016 ER - TY - JOUR AU - Oxnard, G. R. AU - Paweletz, C. P. AU - Kuang, Y. AU - Mach, S. L. AU - O’Connell, A. AU - Messineo, M. M. PY - 2014 DA - 2014// TI - Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2482 DO - 10.1158/1078-0432.CCR-13-2482 ID - Oxnard2014 ER - TY - JOUR AU - Bahcall, M. AU - Sim, T. AU - Paweletz, C. P. AU - Patel, J. D. AU - Alden, R. S. AU - Kuang, Y. PY - 2016 DA - 2016// TI - Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0686 DO - 10.1158/2159-8290.CD-16-0686 ID - Bahcall2016 ER - TY - JOUR AU - Gray, J. AU - Haura, E. PY - 2014 DA - 2014// TI - Update on third-generation EGFR tyrosine kinase inhibitors JO - Transl Lung Cancer Res VL - 3 ID - Gray2014 ER - TY - JOUR AU - Wu, J. AU - Savooji, J. AU - Liu, D. PY - 2016 DA - 2016// TI - Second- and third-generation ALK inhibitors for non-small cell lung cancer JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0251-8 DO - 10.1186/s13045-016-0251-8 ID - Wu2016 ER - TY - JOUR AU - Corcoran, R. B. AU - Atreya, C. E. AU - Falchook, G. S. AU - Kwak, E. L. AU - Ryan, D. P. AU - Bendell, J. C. PY - 2015 DA - 2015// TI - Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.63.2471 DO - 10.1200/JCO.2015.63.2471 ID - Corcoran2015 ER - TY - JOUR AU - Corcoran, R. B. AU - André, T. AU - Yoshino, T. AU - Bendell, J. C. AU - Atreya, C. E. AU - Schellens, J. H. M. PY - 2016 DA - 2016// TI - Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) JO - Ann Oncol VL - 27 ID - Corcoran2016 ER - TY - JOUR AU - Oddo, D. AU - Sennott, E. M. AU - Barault, L. AU - Valtorta, E. AU - Arena, S. AU - Cassingena, A. PY - 2016 DA - 2016// TI - Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-16-0396 DO - 10.1158/0008-5472.CAN-16-0396 ID - Oddo2016 ER - TY - JOUR AU - Samatar, A. A. AU - Poulikakos, P. I. PY - 2014 DA - 2014// TI - Targeting RAS-ERK signalling in cancer: promises and challenges JO - Nat Rev Drug Discov VL - 13 UR - https://doi.org/10.1038/nrd4281 DO - 10.1038/nrd4281 ID - Samatar2014 ER - TY - JOUR AU - Juric, D. AU - Castel, P. AU - Griffith, M. AU - Griffith, O. L. AU - Won, H. H. AU - Ellis, H. PY - 2015 DA - 2015// TI - Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor JO - Nature VL - 518 UR - https://doi.org/10.1038/nature13948 DO - 10.1038/nature13948 ID - Juric2015 ER - TY - JOUR AU - Gainor, J. F. AU - Dardaei, L. AU - Yoda, S. AU - Friboulet, L. AU - Leshchiner, I. AU - Katayama, R. PY - 2016 DA - 2016// TI - Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0596 DO - 10.1158/2159-8290.CD-16-0596 ID - Gainor2016 ER - TY - JOUR AU - Shaw, A. T. AU - Friboulet, L. AU - Leshchiner, I. AU - Gainor, J. F. AU - Bergqvist, S. AU - Brooun, A. PY - 2016 DA - 2016// TI - Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1508887 DO - 10.1056/NEJMoa1508887 ID - Shaw2016 ER - TY - JOUR AU - Sanchez-Martin, F. J. AU - Bellosillo, B. AU - Gelabert-Baldrich, M. AU - Dalmases, A. AU - Canadas, I. AU - Vidal, J. PY - 2016 DA - 2016// TI - The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2400 DO - 10.1158/1078-0432.CCR-15-2400 ID - Sanchez-Martin2016 ER - TY - JOUR AU - Arena, S. AU - Siravegna, G. AU - Mussolin, B. AU - Kearns, J. D. AU - Wolf, B. B. AU - Misale, S. PY - 2016 DA - 2016// TI - MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations JO - Sci Transl Med VL - 8 UR - https://doi.org/10.1126/scitranslmed.aad5640 DO - 10.1126/scitranslmed.aad5640 ID - Arena2016 ER - TY - JOUR AU - Infante, J. R. AU - Janku, F. AU - Tolcher, A. W. AU - Patel, M. R. AU - Sullivan, R. J. AU - Flaherty, K. PY - 2015 DA - 2015// TI - Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors JO - J Clin Oncol VL - 33 ID - Infante2015 ER - TY - JOUR AU - Morris, E. J. AU - Jha, S. AU - Restaino, C. R. AU - Dayananth, P. AU - Zhu, H. AU - Cooper, A. PY - 2013 DA - 2013// TI - Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors JO - Cancer Discov VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-13-0070 DO - 10.1158/2159-8290.CD-13-0070 ID - Morris2013 ER - TY - JOUR AU - Wong, D. J. AU - Robert, L. AU - Atefi, M. S. AU - Lassen, A. AU - Avarappatt, G. AU - Cerniglia, M. PY - 2014 DA - 2014// TI - Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma JO - Mol Cancer VL - 13 UR - https://doi.org/10.1186/1476-4598-13-194 DO - 10.1186/1476-4598-13-194 ID - Wong2014 ER - TY - JOUR AU - Trunzer, K. AU - Pavlick, A. C. AU - Schuchter, L. AU - Gonzalez, R. AU - McArthur, G. A. AU - Hutson, T. E. PY - 2013 DA - 2013// TI - Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.7888 DO - 10.1200/JCO.2012.44.7888 ID - Trunzer2013 ER - TY - JOUR AU - Whittaker, S. R. AU - Cowley, G. S. AU - Wagner, S. AU - Luo, F. AU - Root, D. E. AU - Garraway, L. A. PY - 2015 DA - 2015// TI - Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-15-0136-T DO - 10.1158/1535-7163.MCT-15-0136-T ID - Whittaker2015 ER - TY - JOUR AU - Hayes, T. K. AU - Neel, N. F. AU - Hu, C. AU - Gautam, P. AU - Chenard, M. AU - Long, B. PY - 2016 DA - 2016// TI - Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression JO - Cancer Cell VL - 29 UR - https://doi.org/10.1016/j.ccell.2015.11.011 DO - 10.1016/j.ccell.2015.11.011 ID - Hayes2016 ER - TY - JOUR AU - Manchado, E. AU - Weissmueller, S. AU - Morris, J. P. AU - Chen, C. C. AU - Wullenkord, R. AU - Lujambio, A. PY - 2016 DA - 2016// TI - A combinatorial strategy for treating KRAS-mutant lung cancer JO - Nature VL - 534 UR - https://doi.org/10.1038/nature18600 DO - 10.1038/nature18600 ID - Manchado2016 ER - TY - JOUR AU - Hatzivassiliou, G. AU - Song, K. AU - Yen, I. AU - Brandhuber, B. J. AU - Anderson, D. J. AU - Alvarado, R. PY - 2010 DA - 2010// TI - RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth JO - Nature VL - 464 UR - https://doi.org/10.1038/nature08833 DO - 10.1038/nature08833 ID - Hatzivassiliou2010 ER - TY - JOUR AU - Poulikakos, P. I. AU - Zhang, C. AU - Bollag, G. AU - Shokat, K. M. AU - Rosen, N. PY - 2010 DA - 2010// TI - RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF JO - Nature VL - 464 UR - https://doi.org/10.1038/nature08902 DO - 10.1038/nature08902 ID - Poulikakos2010 ER - TY - JOUR AU - Peng, S. B. AU - Henry, J. R. AU - Kaufman, M. D. AU - Lu, W. P. AU - Smith, B. D. AU - Vogeti, S. PY - 2015 DA - 2015// TI - Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers JO - Cancer Cell VL - 28 UR - https://doi.org/10.1016/j.ccell.2015.08.002 DO - 10.1016/j.ccell.2015.08.002 ID - Peng2015 ER - TY - JOUR AU - Atefi, M. AU - Titz, B. AU - Avramis, E. AU - Ng, C. AU - Wong, D. J. AU - Lassen, A. PY - 2015 DA - 2015// TI - Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma JO - Mol Cancer VL - 14 UR - https://doi.org/10.1186/s12943-015-0293-5 DO - 10.1186/s12943-015-0293-5 ID - Atefi2015 ER - TY - JOUR AU - Lamba, S. AU - Russo, M. AU - Sun, C. AU - Lazzari, L. AU - Cancelliere, C. AU - Grernrum, W. PY - 2014 DA - 2014// TI - RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells JO - Cell Rep VL - 8 UR - https://doi.org/10.1016/j.celrep.2014.07.033 DO - 10.1016/j.celrep.2014.07.033 ID - Lamba2014 ER - TY - JOUR AU - Lito, P. AU - Saborowski, A. AU - Yue, J. AU - Solomon, M. AU - Joseph, E. AU - Gadal, S. PY - 2014 DA - 2014// TI - Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors JO - Cancer Cell VL - 25 UR - https://doi.org/10.1016/j.ccr.2014.03.011 DO - 10.1016/j.ccr.2014.03.011 ID - Lito2014 ER - TY - JOUR AU - Bunda, S. AU - Burrell, K. AU - Heir, P. AU - Zeng, L. AU - Alamsahebpour, A. AU - Kano, Y. PY - 2015 DA - 2015// TI - Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms9859 DO - 10.1038/ncomms9859 ID - Bunda2015 ER - TY - JOUR AU - Garcia Fortanet, J. AU - Chen, C. H. AU - Chen, Y. P. AU - Chen, Z. AU - Deng, Z. AU - Firestone, B. PY - 2016 DA - 2016// TI - Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor JO - J Med Chem VL - 59 UR - https://doi.org/10.1021/acs.jmedchem.6b00680 DO - 10.1021/acs.jmedchem.6b00680 ID - Garcia Fortanet2016 ER - TY - JOUR AU - Chen, Y. N. AU - LaMarche, M. J. AU - Chan, H. M. AU - Fekkes, P. AU - Garcia-Fortanet, J. AU - Acker, M. G. PY - 2016 DA - 2016// TI - Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases JO - Nature VL - 535 UR - https://doi.org/10.1038/nature18621 DO - 10.1038/nature18621 ID - Chen2016 ER - TY - JOUR AU - Bozic, I. AU - Reiter, J. G. AU - Allen, B. AU - Antal, T. AU - Chatterjee, K. AU - Shah, P. PY - 2013 DA - 2013// TI - Evolutionary dynamics of cancer in response to targeted combination therapy JO - Elife VL - 2 UR - https://doi.org/10.7554/eLife.00747 DO - 10.7554/eLife.00747 ID - Bozic2013 ER - TY - JOUR AU - Hrustanovic, G. AU - Olivas, V. AU - Pazarentzos, E. AU - Tulpule, A. AU - Asthana, S. AU - Blakely, C. M. PY - 2015 DA - 2015// TI - RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3930 DO - 10.1038/nm.3930 ID - Hrustanovic2015 ER - TY - JOUR AU - Misale, S. AU - Bozic, I. AU - Tong, J. AU - Peraza-Penton, A. AU - Lallo, A. AU - Baldi, F. PY - 2015 DA - 2015// TI - Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms9305 DO - 10.1038/ncomms9305 ID - Misale2015 ER - TY - JOUR AU - Siravegna, G. AU - Mussolin, B. AU - Buscarino, M. AU - Corti, G. AU - Cassingena, A. AU - Crisafulli, G. PY - 2015 DA - 2015// TI - Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3870 DO - 10.1038/nm.3870 ID - Siravegna2015 ER - TY - JOUR AU - Javle, M. M. AU - Shroff, R. T. AU - Zhu, A. AU - Sadeghi, S. AU - Choo, S. AU - Borad, M. J. PY - 2016 DA - 2016// TI - A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/jco.2016.34.4_suppl.335 DO - 10.1200/jco.2016.34.4_suppl.335 ID - Javle2016 ER - TY - JOUR AU - Goyal, L. AU - Saha, S. K. AU - Liu, L. Y. AU - Siravegna, G. AU - Leshchiner, I. AU - Ahronian, L. G. PY - 2017 DA - 2017// TI - Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1000 DO - 10.1158/2159-8290.CD-16-1000 ID - Goyal2017 ER -